Concepedia

Zhenghong Peng

ZP

Statistics

Publications

22

Citations

1.4K

H-Index

17

Active since

2007

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

University of Michigan

Roche (China)

Beth Israel Deaconess Medical Center

Harvard University

Zhenghong Peng is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, radiation oncology, and cancer research.

Top concepts

Publications per year

2007–2020

22

Publications

22

Association Between Imatinib-Resistant BCR-ABL Mutation-Negative Leukemia and Persistent Activation of LYN Kinase

Ji Yuan Wu, Feng Meng, Ling-Yuan Kong et al. · JNCI Journal of the National Cancer Institute · 2008 · 165 citations · Full text

An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic

Ariel Fernández, Ángela Sanguino, Zhenghong Peng et al. · Journal of Clinical Investigation · 2007 · 161 citations · Full text

, , +13

Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In Vivo

Jieru Meng, Bingbing Dai, Bingliang Fang et al. · PLoS ONE · 2010 · 146 citations · Full text

, , +18

Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells

Ji Yuan Wu, Feng Meng, Henry Y. Lu et al. · Blood · 2008 · 109 citations · Full text

SF2312 is a natural phosphonate inhibitor of enolase

Paul G. Leonard, Nikunj Satani, David S. Maxwell et al. · Nature Chemical Biology · 2016 · 97 citations · Full text

, , +5

1–5 of 22